Engineered T Cells May Boost Melanoma Treatment Yervoy

Like many cancer treatments, recently approved melanoma drug ipilimumab (Yervoy, Bristol Myers Squibb Co.), is great for those patients in whom it works – meaning, not that many. In Yervoy's case, the response rate is about 15 percent. (See BioWorld Today, March 28, 2011, and March 23, 2011.)